首页> 美国卫生研究院文献>American Journal of Physiology - Gastrointestinal and Liver Physiology >Tetrahydrobiopterin (BH4) a cofactor for nNOS restores gastric emptying and nNOS expression in female diabetic rats
【2h】

Tetrahydrobiopterin (BH4) a cofactor for nNOS restores gastric emptying and nNOS expression in female diabetic rats

机译:四氢生物蝶呤(BH4)是nNOS的辅助因子可恢复雌性糖尿病大鼠的胃排空和nNOS表达

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Gastroparesis is a debilitating disease predominantly affecting young women. Recently, dysregulation of neuronal nitric oxide synthase (nNOS) in myenteric plexus neurons has been implicated for delayed solid gastric emptying/gastroparesis in diabetic patients. In this study, we have explored the role of tetrahydrobiopterin (BH4), a major cofactor for nNOS activity and NO synthesis in diabetic gastroparesis. Diabetes was induced with single injection of streptozotocin (55 mg/kg body wt, ip) in female rats, with experiments performed on week 3 or 9 following induction, with or without 3-wk BH4 supplementation. Gastric pyloric BH4 levels were significantly decreased in diabetic female rats compared with control (18.6 ± 1.45 vs. 31.0 ± 2.31 pmol/mg protein). In vitro studies showed that 2,4-diamino-6-hydroxypyrimidine (DAHP), an inhibitor of BH4 synthesis, significantly decreased gastric NO release and nitrergic relaxation. Three-week dietary supplementation of BH4 either from day 1 or week 6 significantly attenuated diabetes-induced delayed gastric emptying for solids (3 wk: BH4, 67 ± 6.7 vs. diabetic, 36.05 ± 7.09; 9 wk: BH4, 57 ± 8.45 vs. diabetic, 33 ± 9.91) and diabetes-induced reduction in pyloric nNOS-α protein expression in female rats. Supplementation of BH4 significantly restored gastric nNOS-α dimerization in 9-wk-old diabetic female rats. In addition, BH4 treatment reversed (17.23 ± 5.81 vs. 42.0 ± 2.70 mmHg × s) the diabetes-induced changes in intragastric pressures (IGP) and gastric pyloric nitrergic relaxation (−0.62 ± 0.01 vs. −0.22 ± 0.07). BH4 deficiency plays a critical role in diabetes-induced alterations including delayed solid gastric emptying, increased IGP, reduced pyloric nitrergic relaxation, and nNOS-α expression in female rats. Supplementation of BH4 accelerates gastric emptying by restoring nitrergic system in diabetic female rats. Therefore, BH4 supplementation is a potential therapeutic option for female patients of diabetic gastroparesis.
机译:胃轻瘫是一种衰弱性疾病,主要影响年轻妇女。近来,在糖尿病性患者中,肌间神经丛神经元中神经元一氧化氮合酶(nNOS)的失调与延迟的固体胃排空/胃轻瘫有关。在这项研究中,我们探讨了四氢生物蝶呤(BH4)的作用,它是糖尿病性胃轻瘫中nNOS活性和NO合成的主要辅助因子。在雌性大鼠中单次注射链脲佐菌素(55 mg / kg体重,腹膜内)诱导糖尿病,诱导后第3周或第9周进行实验,添加或不添加3周BH4。与对照组相比,糖尿病雌性大鼠的胃幽门BH4水平显着降低(18.6±1.45 vs. 31.0±2.31 pmol / mg蛋白)。体外研究表明,BH4合成抑制剂2,4-二氨基-6-羟基嘧啶(DAHP)显着降低了胃NO释放和硝化舒张。从第1天或第6周开始的三周饮食补充BH4可以显着减轻糖尿病引起的胃排空延迟(3周:BH4,67±6.7 vs.糖尿病,36.05±7.09; 9周:BH4,57±8.45 vs糖尿病(33±9.91)和糖尿病引起的雌性大鼠幽门nNOS-α蛋白表达降低。补充BH4可在9周龄的糖尿病雌性大鼠中显着恢复胃nNOS-α二聚化。此外,BH4治疗逆转(17.23±5.81对42.0±2.70 mmHg×s),由糖尿病引起的胃内压(IGP)和胃幽门硝化舒张性改变(-0.62±0.01对-0.22±0.07)。 BH4缺乏症在糖尿病引起的改变中起关键作用,包括延迟固胃排空,IGP增加,幽门硝化舒张减少和雌性大鼠nNOS-α表达。补充BH4可通过恢复糖尿病雌性大鼠的硝化系统来加速胃排空。因此,补充BH4是女性糖尿病性胃轻瘫患者的潜在治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号